Indian Equities Close Higher, Overcoming a Choppy Session

Synopsis:


Indian equities ended Tuesday’s session higher, with Sensex and Nifty 50 rising 0.39%. IT led sectoral gains, while Oil & Gas, Realty, and PSU Banks faced pressure. Midcaps and smallcaps showed steady participation, with Infosys as the top gainer.


Welcome to the Bajaj Broking Markets Daily Podcast. Here’s your evening market wrap for Tuesday, September 9, 2025. Don’t forget to check out our Evening Podcast for more updates!

Also Read: Stock Market Live Updates

Indian Equities Closed Higher Today, Overcoming a Choppy Session

Market Overview

Indian equities closed higher today, overcoming a choppy and range-bound session, buoyed by firm global cues ahead of key US and India CPI data later this week.

At the closing bell, the Sensex gained 314 points, or 0.39%, to settle at 81,101, while the Nifty 50 advanced 95 points, also up 0.39%, to close at 24,868.

Also Read: Dabur’s NewU Partners with Unicommerce for Easy Shopping 

Sectoral Performance

On the sectoral front, Nifty IT led the rally with strong momentum in technology stocks. Pharma and FMCG sectors offered defensive support, while Oil & Gas, Realty, and PSU Banks faced pressure, limiting broader market gains.

Also Read: SpiceJet Clears $24 M Credit Suisse Dues, Marks Liabilities Closure

Infosys Limited

Trade

1300.825.10 (1.96 %)

Updated - 02 April 2026
1305.40day high
DAY HIGH
1259.80day low
DAY LOW
11223276
VOLUME (BSE)

Broader Market Trends

Resilience was visible beyond large caps as the Nifty Midcap 100 rose 0.18% and the Nifty Smallcap 100 climbed 0.34%, reflecting steady participation across market segments.

Top Movers

Among individual performers, Infosys surged nearly 4.85%, emerging as a top gainer, while Trent slipped 1.74%, ranking among the key laggards.

That’s all for today’s market highlights. Stay tuned with Bajaj Broking for more daily insights and updates to guide your investment decisions.

Also Read: Mankind Pharma Receives CDSCO Nod for Phase 1 Trial of Autoimmune Drug

Don’t forget to subscribe to our podcast.

Share this article: 

Published Date : 09 Sep 2025

Disclaimer :

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 lakh+ Users

icon-with-text

4.7 App Rating

icon-with-text

4 Languages

icon-with-text

₹7,300+ Cr MTF Book

icon-with-text